Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH

Southeast Retina Center, Georgia24 enrolled

Overview

This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days but \>7 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group). Follow-up visits occur 1 day and 1-2 weeks, and 4 weeks postoperatively and then every 4 weeks from the first postoperative IAI for 52 weeks. One preoperative visit and every postoperative visit (except day one postoperatively) will include ETDRS Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP) measurement, Slit lamp biomicroscopy, Indirect ophthalmoscopy, Heidelberg Spectralis Spectral Domain Optical Coherence Tomography (SD-OCT) (no OCT for preoperative visit) and evaluation for systemic and ocular adverse events. Seven standard field photographs and Optos wide-field fluorescein angiography will be performed at postoperative visits at 4, 16, 28, 40,and 52 weeks. Humphrey visual field (HVF) testing (30-2 and 60-4 test patterns) will be performed at postoperative visits at 4 and 52 weeks. Preoperative B scan echography will be required standard of care(SOC) to assess for macular traction, non-macular traction, retinal detachment and vitreous hemorrhage(VH). Identification of traction macular detachment will exclude the patient from the study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

Conditions

Proliferative Diabetic Retinopathy

Interventions

AfliberceptDRUG

. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.

Endolaserless VitrectomyPROCEDURE

Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adults age \>18 years with Diabetes Mellitus 2. PDR- related vitreous hemorrhage and not of another cause 3. BCVA Vision LP or better 4. Investigator determination that vitrectomy indicated for PDR-related vitreous hemorrhage 5. Willing and able to comply with clinic visits and study-related procedures 6. Provide HIPPA and signed informed consent prior to any study procedures Exclusion Criteria: 1. A condition per investigator opinion, would preclude participation in the study (unstable medical status, cardiovascular disease, glycemic control, inability to follow up etc.) 2. Participation in an investigational trial within 30 days of enrollment 3. Known allergy to IAI 4. Systemic anti-VEGF or pro-VEGF treatment within 4 months of enrollment 5. For women of childbearing age, pregnant or lactating or intending to become pregnant within the next 3 years 6. History of PRP or peripheral retinal cryopexy or peripheral retinopexy for any reason in the study eye 7. History of vitrectomy in the study eye 8. History or evidence for rhegmatogenous retinal detachment in the study eye 9. Evidence of traction retinal detachment involving or threatening central macula in the study eye 10. Exam evident of external ocular infection (i.e. conjunctivitis, significant blepharitis, chalazion etc) 11. Intravitreal anti-VEGF injection in the study eye \<4weeks from enrollment. 12. Pregnant or breast-feeding women 13. Sexually active men\* or women of childbearing potential\*\* who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device \[IUD\]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) \*Contraception is not required for men with documented vasectomy. \*\*Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

Locations (1)

Southeast Retina Center, PC

Augusta, Georgia, United States

RECRUITING

Outcomes

Primary Outcomes

• Ocular and systemic safety evaluation for adverse events at any time point through 52 weeks:

Examples include worsened acuity \>30 letters, rhegmatogenous or tractional retinal detachment, endophthalmitis, new or increased vitreous hemorrhage, cataract progression or surgery, need for additional vitrectomy or scleral buckle, development of new DME after OCT documentation of absence of DME, systemic thromboembolic events, deaths and systemic serious adverse events at any time point through week 52.

Time frame: Through 52 weeks from Baseline

Secondary Outcomes

Mean change in BCVA letter score

Mean change in BCVA letter score over time through week 52

Time frame: 52 weeks from Baseline

Mean BCVA letter score

Mean BCVA letter score over time through week 52

Time frame: 52 weeks from Baseline

Proportion of eyes with progression of PDR

Proportion of eyes with progression of PDR as defined above at any time point through week 52

Time frame: Through 52 weeks from Baseline

Mean OCT CSF thickness

Mean OCT CSF thickness over time through week 52

Time frame: Through 52 weeks from Baseline

Proportion of eyes with OCT CSF thickness <300um

Proportion of eyes with OCT CSF thickness \<300um at week 52

Time frame: Through 52 weeks from Baseline

Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage

Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage at week 52

Central Contacts

Dennis M Marcus, MD

CONTACT

706-650-0061 dmarcus@southeastretina.com

Siobhan Ortiz

CONTACT

706-650-0061 siobhan@southeastretina.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.